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Abstract
Bone is the most prevalent metastatic site for breast cancer affecting ~70% of patients with late-stage disease. 
Treatments for this condition currently focus on controlling disease progression and limiting tumour-induced 
damage to bone, thereby playing a valuable role in increasing quality of life. However, limited understanding of the 
interplay between tumour cells and their environment during bone metastasis has impeded the development of 
curative treatments. To unravel the complex genetic and phenotypic alterations that occur during this process, it 
would be helpful to have a model in which tumours develop spontaneously at the primary site, spread to bone, 
undergo a dormancy phase and then, after a fixed timeframe, become re-activated to form osteolytic/mixed 
lesions in the skeleton. Unlike humans, spontaneous metastasis of primary mammary tumours to bone is rare in 
mice and no syngeneic models of oestrogen receptor positive disease have been reported. As there is no single 
model that authentically reproduces all of the genetic and phenotypic changes representative of human bone 
metastasis, this review discusses the traditional and novel mouse models that are used to study bone metastasis 
from breast cancer. Additionally, this review focuses on advances that have been made towards making these 
models more closely related to human disease in an attempt to help researchers select the correct model(s) for 
their experimental needs with the aim of improving translational efficacy between the laboratory and the clinic.
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INTRODUCTION
Bone is a common metastatic site for breast cancer and is most prevalent from oestrogen receptor (ER)-
positive disease[1]. Once in bone, cancers are currently considered to be incurable and life expectancy for 
patients’ drops to just 2-4 years following diagnosis of bone involvement[2]. It is therefore imperative that 
researchers better understand the mechanisms that drive the different stages of the bone metastatic process 
to enable development of more effective and curative therapies.
Metastasis is a complex, multistep process involving genetic and phenotypic changes in tumour cells and 
cells within the local environment. In addition, evidence suggests that signalling between tumour cells and 
bone cells is an early event, in which tumour cells at the primary site produce microRNAs and other 
secreted factors, such as Lysyl oxidase and interleukin 1 beta, that prime bone for receiving metastatic cells 
and in return bone cells secrete chemo attractants that promote tumour cell homing to this site[3-6]. The 
complex nature of this process necessitates the use of whole-body organisms. However, unlike humans, 
spontaneous metastasis of primary mammary tumours to bone is rare in mice and no syngeneic models of 
ER-positive disease have been reported. To date, there is no single model that authentically reproduces all of 
the genetic and phenotypic changes representative of human bone metastasis, therefore researchers must 
select the most appropriate model(s) to test their hypotheses. In this review, we discuss the traditional and 
novel mouse models that are used to study bone metastasis from breast cancer, focusing on advances that 
have been made towards making these models more closely related to human disease in an attempt to 
improve translational efficacy between the laboratory and the clinic.
BREAST CANCER BONE METASTASIS; WHAT ARE WE TRYING TO MODEL?
Seventy to eight per cent of patients with late-stage breast cancer will develop bone metastasis and the 
majority of these patients will have ER-positive disease[1]. Dissemination of tumour cells into bone is 
believed to be an early event, often occurring before clinical detection of the primary tumour. However, 
overt metastases do not usually develop until many years later[1]. When tumour cells arrive in the bone 
microenvironment, they home to the bone metastatic niche (comprised of the endosteal/haematopoietic 
stem cell and peri-vascular niches)[7,8]. Interactions between tumour cells and the niche(s) promote tumour 
cell dormancy and/or metastatic outgrowth, dependent upon a number of factors including tumour volume, 
stage, molecular sub-type and environmental conditions. Typically, ER-negative tumours display a more 
aggressive phenotype with disease recurrence peaking around two years after diagnosis and relapse rate 
reducing to low levels > 5 years after diagnosis. Whereas less aggressive ER-positive breast cancer has a long 
latency, with low risk of recurrence in the initial five years after diagnosis, the risk of recurrence increasing 
annually after five years following both diagnosis and surgical removal of the primary tumour[9]. 
Interestingly, the 15-year recurrence is similar in both ER-negative and ER-positive disease, suggesting that 
both molecular subtypes contain a population of cells capable of undergoing long-term dormancy in 
bone[10]. It is believed that long periods of latency associated with bone metastasis are due to disseminated 
tumour cells either needing time to alter their new environment to enable increased metastatic outgrowth of 
tumour cells through expansion of the metastatic niche(s)/suppression of immune regulation or waiting 
until external factors alter the local microenvironment in a manner that promotes tumour growth. Once 
tumour cells begin to outgrow into overt metastasis in bone, they stimulate increased resorption of the bone 
matrix, through receptor activator of nuclear factor κ B (RANK)/RANK ligand (RANKL)-induced 
activation of osteoclasts, resulting in the formation of osteolytic lesions in the affected bone and release of 
matrix-bound cytokines, including interleukin 6 (IL-6) and tumour necrosis factor alpha (TNFα), which 
feedback onto the tumour cells further stimulating their growth. These interactions between tumour cells 
and bone cells cause a positive feedback loop known as the vicious cycle of bone metastasis 
(reviewed in[11,12]). It must be noted, however, that bone metastases from breast cancers are not exclusively 
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osteolytic, and secretion of growth factors including epidermal growth factors, bone morphogenic proteins 
and platelet derived growth factors from tumour cells increase osteoblast activity, resulting in the 
production of mixed lesions which can be observed in a subset of patients (reviewed in[13]).
Breast cancer bone metastasis is a complex process involving many signalling pathways and cell types, and 
there are potentially variations in mechanisms that drive metastasis from different molecular sub-types. 
Because of this complexity, a variety of in vivo mouse models has been developed to allow researchers to 
investigate specific aspects of this disease process.
MOUSE MODELS
Human breast cancer xenograft models
To facilitate growth of human breast cancer cells in a different species, such as mouse, it is essential to use 
an immunodeficient host. The majority of human breast cancer cells lines that are either trophic to the bone 
environment or form overt tumours following injection directly into bone grow readily in nude mice that 
have been bred on a BALB/c or MF1 background [Table 1][14-19]. These mice have no thymus and therefore 
cannot generate mature T lymphocytes and are unable to mount many types of adaptive immune responses 
including graft rejection[20]. Some, more difficult to culture cell lines as well as patient derived xenografts 
(PDXs) will only graft/grow in more severely immunocompromised mice. For these models, NOD SCID 
mice that have severe immunodeficiency affecting T and B lymphocyte development as well as having 
reduced NK cells, macrophages and granulocytes numbers and functionality can be utilized[21-23]. There has 
been a recent trend amongst researchers to move towards the use of even more severely 
immunocompromised, NOD SCID ϒ (NSG) mice, for grafting PDXs, as these animals are deficient in 
multiple cytokine signalling pathways as well as those seen in NOD SCID mice increasing the likelihood of 
successful tumour engraftment[23,24]. Because immune response has profound effects on tumorigenesis and 
the activity of many anti-cancer agents [Table 2], data obtained from these models must be interpreted 
cautiously.
Immortalised breast cancer cell lines
Injecting human bone trophic breast cancer cell lines into the blood stream of young (4-8 weeks old) mice is 
the most commonly used model for generating bone metastases in the laboratory. This method is useful for 
investigating tumour cell homing, colonisation, metastatic outgrowth and associated interactions with the 
bone microenvironment as well as therapeutics. Injection of human triple negative, MDA-MB-231, or ER-
positive, MCF7, cells into the left cardiac ventricle or carotid artery in appropriate mouse strains results in 
tumour growth in the long bones spine and jaw [Table 1][6,14,16,17,25]. This method works particularly well with 
MDA-MB-231 cells from which osteolytic tumours develop in 60%-90% of animals 2-4 weeks following 
injection. Bone metastasis from MCF7 cells form mixed (lytic/blastic) lesions, however these occur less 
frequently, over an extended time period (20-25 weeks) and often require oestradiol supplementation[26]. 
Data showing bone metastases from intra-cardiac injection of other human breast cancer cell lines are 
lacking, suggesting that this is an infrequent event. The high propensity of MDA-MB-231 cells to 
metastasise to bone following intra-cardiac injection has resulted in this becoming the model of choice for 
many researchers, but this model is not without its limitations:
· The majority of bone metastasis from breast cancers, in humans, occur from ER-positive rather than ER-
negative disease represented by MDA-MB-231 cells.
· Bone metastasis is associated with tumour cells, from the primary site, homing to specific metastatic niches 
in bone and undergoing long periods of dormancy in these sites before outgrowth into overt metastasis. The 
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Table 1. Summary of immune compromised mouse models of breast cancer bone metastasis
Cell line Origin Sub-line Model system Inoculation route Metastatic site Lesion
Intra-cardiac Mouse long bones, 
spine and jaw
Osteolytic 2-3 weeks







Orthotopic (MIND) Human bone x-plants Osteolytic 4-7 weeks
Intra-cardiac 
Intra-arterial






Intra-tibial Mouse tibiae Osteolytic 1-2 weeks
BALB/c nude Intra-cardiac 
Intra-arterial 
Intra-venous

























Intra-tibial Mouse tibiae Osteolytic 2-3 weeks
Orthotopic (fat pad) Human bone X-plants Osteolytic 4-8 weeksSUM-
1315








Intra-tibial Mouse tibiae Osteolytic 3-4 weeks
Intra-cardiac Mouse long bones Mixed 20-25 weeks
Intra-tibial Mouse tibiae Mixed 1-3 weeks
BALB/c nude





NOD SCID Orthotopic (fat pad) Mouse long bones 
Human X-plants
Mixed 6-8 weeks




isolated from a 
pleural effusion
MCF-7/Neu BALB/c nude
Intra tibial Mouse long bones Mixed 1-3 weeks
Intra-cardiac Mouse long bones Mixed 20-25 weeks
Intra-tibial Mouse tibiae Mixed 1-3 weeks
BALB/c nude











NOD SCID Orthotopic (fat pad) Mouse long bones 
Human X-plants
Mixed 6-8 weeks
ZR75-1 Human ductal 
carcinoma 





BALB/c nude Intra-cardiac Mouse long bones and 
spine
Mixed 12-25 weeks
Orthotopic (MIND) Mouse long bones, 
lungs and human bone 
X-plants










Intra-cardiac Mouse long bones, 
lungs and human bone 
X-plants
Lytic 14+ weeks
Orthotopic (MIND) Mouse long bones, 
lungs and human bone 
X-plants









Intra-cardiac Mouse long bones, 
lungs and human bone 
X-plants
Lytic 15+ weeks
Orthotopic (MIND) Mouse long bones, 

















Intra-cardiac Mouse long bones, 
lungs and human bone 
X-plants
Lytic 15+ weeks
short duration between injection of MDA-MB-231 cells and metastatic outgrowth indicates a lack of 
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Table 2. Summary of immune competent mouse models of breast cancer bone metastasis
Cell 
line Origin Sub-line Model system Inoculation route Metastatic site Lesion
Intra-cardiac Mouse long bones, spine, 




Mouse long bones, spine, 






Intra-osseous Recipient bone Osteolytic 1-3 weeks
Intra-cardiac Mouse long bones, spine, 
jaw, lungs and spleen
Osteolytic 2-3 weeks
Orthotopic (fat pad) Mouse long bones, spine, 
jaw, lungs and spleen
Osteolytic 3-4 weeks
4T1 Mouse isolated 
from stage 1 V 
mammary 







Intra-osseous Recipient bone Osteolytic 1-3 weeks
Intra-cardiac Mouse long bones, spine 
jaw and lungs
Osteolytic 2-3 weeksPyMT 
MMTV
Isolated from a 
mammary 
tumour induced 
by MMTV viral 







Intra-osseous Recipient bone Osteolytic 1-2 weeks
Intra-cardiac 
Intra-tibial
Mouse long bones, spine 
jaw and lungs
Mixed 2-3 weeksE0771 Medullary 
breast 
adenocarcinoma 
isolated from a 
spontaneous 












Mouse long bones, spine, 
lungs and jaw












Orthotopic (MIND) Mouse tibiae Mixed 1-3 weeks
Intra-cardiac Mouse long bones Osteolytic 2-4 weeks
Orthotopic Spine Osteolytic 3-5 weeks
KEP Mouse invasive 
lobular 
carcinoma 













Orthotopic Mouse long bones and 
spine
Osteolytic 6-9 weeks
dormancy phase in this model.
· Bone metastases from parental MDA-MB-231 cells occur randomly (not always in the long bones), 
resulting in large n numbers being required for analysis.
· Intra-cardiac injection requires considerable technical expertise, and even with this ~10% of mice die of 
stroke, due to cells becoming stuck in the circulation, or develop hind limb paralysis resulting in undesirable 
loss of animals.
· The requirement for immune-compromised mice prevents accurate representation of immune response to 
tumours/therapies.
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Considerable amounts of research are therefore being carried out to produce alternative models that can be 
used to answer questions that are less suited to the traditional, MDA-MB-231, intracardiac model. Indeed, 
ER-positive MCF7 and T47D models that display long latency may be more representative of human 
disease and may prove to be useful for investigating efficacy of treatments on mixed lesions, as this 
phenotype is not commonly investigated in mouse models but is observed in a subset breast cancer 
patients[27]. With careful selection of the appropriate model systems researchers now have a fairly 
comprehensive tool set for investigating various aspects of breast cancer bone metastasis [Table 1].
(1) Improving outcome, frequency and molecular subtypes represented in mouse models of breast cancer 
bone metastases
To increase the frequency of bone metastases and reduce the need for intra-cardiac injections, bone seeking 
sub-lines of MDA-MB-231 cells have been produced via repeated in vivo passaging through mouse 
bones[7,15,19,28]; MDA-MB-231-B02, MDA-MB-231-B and MDA-MB-231-bone cells form tumours in up to 
90% of mice following injection into the caudal artery, whereas MDA-IV cells form tumours in 80%-90% of 
mice after injection into the lateral tail vein[7,15,19,28-31]. Via a similar mechanism, of in vivo passaging, 
researchers have also produced a bone seeking MCF7 breast cancer cell line that predominantly forms 
osteolytic lesions after 10-12 weeks[26]. Recently, researchers have reported high incidences of bone 
metastasis from ER-positive MCF7 cells following injection via the caudal artery without the need for 
oestradiol supplementation, suggesting that this method may be useful for modelling bone metastases from 
a wide variety of breast cancer subtypes[25]. Injecting tumour cells via the caudal artery/tail vein appears to 
result in bone metastases primarily forming in the hind limbs, simplifying downstream analysis and 
allowing reduced numbers of animals to be used for statistical analysis. Importantly, these methods are not 
associated with stroke or early hind limb paralysis, reducing risks of adverse events that are commonly 
observed following intra-cardiac injection.
Many breast cancer cell lines do not form bone metastases following injection into the blood stream. For the 
majority of these, bone metastases can be modelled by direct injection into the tibia or femur, which results 
in the development of osteolytic tumours in the corresponding bone. This method has successfully been 
used to model interactions between the bone microenvironment and tumour cells and has shown efficacy as 
a method for xenografting ER-negative MDA-MB-231, MDA-MB-436 and SUM 1315 cells as well as PDXs 
and ER-positive MCF7 or T47D cells following oestradiol supplementation[32-36]. This method has the 
advantage of high tumour take rates in bone and is useful for studying genetic manipulation of the 
host/tumour cell environment. However, intra-osseous injection results in considerable damage to the bone 
cortex and displaces cells within the marrow cavity promoting increased cytokine release and bone turnover 
during the healing process; these factors must be taken into account when analysing data acquired using this 
method. Furthermore, intra-osseous injection bypasses the early stages of metastasis including homing to 
the bone microenvironment and tumour cells do not need to interact with the bone metastatic niche from 
which bone metastases normally develop. Intra-osseous injection cannot therefore be used to model tumour 
cell dormancy or early stages of metastases.
(2) Modelling bone homing with human breast cancer xenografts
Injection of breast cancer cells into the left cardiac ventricle or caudal artery results in tumour cells being 
disseminated into the skeleton via the arterial system. It has been argued that these cells do not home to 
bone; instead, tumour cells become trapped in the capillaries, from which they then migrate to the 
metastatic niche(s). Therefore, this is not an appropriate model for investigating mechanisms associated 
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with bone homing[15]. Injection into the lateral tail vein may better model bone homing, as tumour cells 
introduced into the venous circulation in this manner need to make at least one pass through the circulatory 
system before being disseminated in bone. Indeed, introduction of most cell lines into the lateral tail vein 
results in tumour growth in the lungs and only cells “homed” to bone produce bone metastases with this 
method[37]. However, studies comparing specific molecular profiles of MDA-MB-231 cells that for form 
bone metastases following intra-cardiac injection (MDA-MB-231-B02) and clones of MDA-MB-231 cells 
that form bone metastasis following intra-venous injection (MDA-MB-231-IV) have demonstrated that 
both of these clones show bone homing profiles and that these clones are more closely related to each other 
than to the parental clone[15,19,30]. Furthermore, intra-cardiac and intra-venous injection of bone homing 
clones of MDA-MB-231 cells results in tumour cell dissemination into the same metastatic niches 
(endosteal and peri-vascular) indicating that both models are equally as useful for studying processes 
associated with early dissemination into bone but may be less useful for identifying mechanisms associated 
with bone homing[38].
In breast cancer patients, it is believed that tumour cells at the primary site “prime” the bone for arrival of 
disseminating tumour cells, facilitating metastasis to this site[39]. This process is difficult to model in mice as 
human breast cancer cell lines rarely, if ever, spontaneously metastasise from the mammary fat pad to the 
mouse skeleton. Researchers have recently developed ER-positive and ER-negative models of spontaneous 
breast cancer metastasis to bone. In these models, injection of MCF7 or T47D cells into the fourth 
mammary fat pads results in spontaneous metastasis to mouse bone in ~50% of animals[6,23,40]. In addition, 
injection of ER-positive BB3RC2 and BB2RC08 PDXs or ER-negative BB6RC37 PDXs into the fourth 
mammary duct using the MIND model also results in spontaneous metastasis to mouse bone in 32%, 20% 
and 20%. respectively[23]. Interestingly, in all of these models, mice were supplemented with oestradiol to 
support tumour growth. In the MCF7 and T47D models, development of overt bone metastases was 
dependent on mice being supplemented with oestradiol, irrespective of the growth of the primary tumour; 
whether the same is true for these particular PDX models remains to be determined. Because oestradiol has 
profound bone anabolic effects, especially in mice [Figure 1], and can also alter anti-cancer immunity, 
supplementation with this hormone adds complexity to analysing results obtained using these models[2,40].
(3) Breast cancer dormancy models
As metastasis to mouse bone primarily occurs in young, 4 to 8-week-old animals or following oestradiol 
supplementation, it is hypothesised that high bone turnover is necessary to stimulate growth of human 
cancer cells in mouse bone. Researchers have used this idea to generate models in which manipulation of 
the bone environment can be used to investigate factors associated with breast cancer cell dormancy and 
metastatic outgrowth. Dissemination of MDA-MB-231 breast cancer cells into bone via intra-cardiac 
injection results in tumour cells lodging in the bone metastatic niche (primarily close to the growth plate in 
the trabecular region on bone)[38,41]. In adult mice, metastatic outgrowth is rare, possibly due to low rates of 
bone turnover, leading researchers to hypothesise that older “adult” mice may provide a useful model for 
studying dormancy[42]. Labelling tumour cells with lipophilic membrane dyes, such as 1,1-Dioctadecyl-
3,3,3,3-tetramethylindodicarbocyanine (DiD) and 1,1’-Dioctadecyl-3,3,3’,3’-Tetramethylindocarbocyanine 
Perchlorate (DiL), before intra-cardiac injection enables the researcher to differentiate between dormant 
and proliferating cancer cells in bone as the dyes are retained in the membrane of non-proliferating 
(dormant) cells but are progressively lost as cells go through subsequent rounds of proliferation[38,42,43]. Using 
DiD labelled MDA-MB-231 cells, researchers have demonstrated that in adult (14-16 weeks old) mice 
tumours lodge in the bone but remain dormant in this site with metastatic outgrowth occurring in > 10% of 
animals over the 84-day time period tested[43]. Stimulating osteoclastic bone resorption by ovariectomy 
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Figure 1. Effects of oestradiol on mouse tibiae. Eight-week-old BALB/c nu/nu mice received a 28-day release 1.7 mg 17฀ oestradiol pellet 
via subcutaneous implant or 12 mg/L 17฀ oestradiol continually via their drinking water (n = 10/group). Mice were culled after 28 days 
and serum and tibiae isolated for analysis: (A) mean ± SEM circulating concentrations of 17฀ oestradiol as measured by ELISA; (B) 
effects of 17฀ oestradiol on mean ± SEM for percentage of trabecular bone volume compared with tissue volume (BV/TV%) in the 
proximal tibiae; (C) representative, three-dimensional micro-CT images of tibiae from control (untreated) and 17฀-treated tibiae. 
Statistical analysis was by student t-test. **P < 0.01; ***P < 0.001. Data shown are previously unpublished observations from the 
Ottewell laboratory.
results in development of overt metastases in 80%-90% of adult mice even after long-term dormancy[42,43]. 
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There are currently no published data showing that this method of modelling metastatic dormancy/tumour 
outgrowth works for other breast cancer cell types. However, unpublished observations from the Ottewell 
lab suggest that ovariectomy can stimulate metastatic outgrowth tumour cells disseminated in bones of 
adult (14-16 weeks old) C57BL/6 mice following intra-ductal injection of E0771 cells (previously 
unpublished observations from the Ottewell laboratory; Figure 2), suggesting that ovariectomy may be a 
suitable method for modelling dormancy/tumour outgrowth in bone form a wider repertoire of cell lines.
PDX models
Breast cancer cell lines, which are commonly used to model bone metastasis including MDA-MB-231, 
MCF7 and T47D, have been in continuous culture, on plastic, in various laboratories for approximately 40 
years[44,45]. As a result, these cell lines have lost heterogeneity and no longer accurately represent the original 
tumour from which they were isolated. PDXs are tumours that have been cultured in immune-
compromised whole body model systems immediately following surgical removal from the patient. These 
have not been cultured on plastic and for at least a minimal number of passages retain their original 
molecular sub-types and heterogeneity[46]. Thus, there is increasing interest in the use of PDXs to make 
more clinically relevant models of bone metastasis. Surgical implantation of dissociated PDXs into the 
cleared mammary fat pad or surgical engraftment of PDX fragments onto the existing mouse mammary fat 
pads results in tumour growth at the primary site and disseminated tumour cells in the bone marrow from 
both ER-negative breast cancers and a small number of ER-positive breast cancers[47-49]. However, outgrowth 
into overt metastases is very low (15%) compared with development of metastasis in soft tissues such as 
ovaries, lung and liver which have been reported to be up to 100%, 40% and 20%, respectively, from the 
same model[47]. Interestingly, metastatic outgrowth in bone has only been reported in one ER-negative PDX 
model without the use of oestradiol supplementation[47]. Injection of dissociated breast cancer PDXs into 
mice supplemented with oestradiol significantly increases occurrences of overt metastatic lesions. Injecting 
ER+PR+HER2- PDXs (BB3RC32 and BB2RC08) or ER-PR-HER2- PDXs (BB6RC37) into fourth mammary 
ducts of NSG mice, supplemented with oestradiol, resulted in spontaneous metastasis to bone in 75%, 20% 
and 20% of mice and metastasis to lung in 70%, 60% and 100% of mice, respectively[23]. Intracardiac injection 
of the same PDXs into NSG mice further increases overt bone metastases to 80% from ER+PR+HER2- 
BB3RC32 and BB2RC08 cells and 30% from ER-PR-HER2- BB6RC37 cells with lung metastases being 
detected in 40%, 80% and 100% of mice, respectively[23]. Taken together, these data support the idea that 
oestrogen stimulates development of overt metastases in bone, possibly through its anabolic actions, 
stimulating the bone metastatic niches, and both the seed (tumour cells) and soil (bone microenvironment) 
need to be optimal for metastases to develop in this organ.
(1) Models of human breast cancer metastasis to human bone
As discussed above, spontaneous metastasis of human breast cancer cells to mouse bone is rarely observed, 
especially in the absence of interventions that stimulate bone remodelling. Furthermore, strong evidence 
suggests a role for the metastatic niche in homing and colonisation of bone as well as regulating metastatic 
dormancy and growth (reviewed in[39,50]). It is possible that species differences may influence the ability of 
primary tumours to prime the metastatic niche for future arrival of tumour cells and/or regulate tumour cell 
dormancy/outgrowth in this metastatic site. To develop more clinically relevant models, in which human 
breast tumour cells metastasise to a tissue of human origin, researchers have developed mouse models in 
which pieces of human femoral bone are subcutaneously implanted into immunocompromised mice before 
injection of tumour cells[51,52]. Initial publications reported low rates of metastasis to the human bone 
implants from a number of cell lines injected via tail vein or orthotopic implantation, and osteotropism was 
only reported from the SUM1315 breast cancer cell line[51].
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Figure 2. Ovariectomy stimulates metastatic outgrowth of E0771 mammary cancer cells disseminated in bones of syngeneic C57BL/6 
mice. Injection of 2 × 105 E0771 cells into the fourth mammary duct of 12-week-old female C57BL/6 mice resulted in tumour growth at 
the primary site and dissemination of tumour cells into the skeleton (A). Five weeks following ovariectomy, disseminated tumour cells in 
bone were activated to induce overt metastases. These metastatic outgrowths can be observed in the ling bones and lungs (B). Data 
shown are previously unpublished observations from the Ottewell laboratory.
Recent refinements to these human-to-human model systems have led to significant improvements in 
metastasis rates from both ER-positive and ER-negative breast cancers: the sub-chondral portion of femoral 
bone shows increased biological activity compared with spongy bone[53], and haematopoiesis is retained in 
this tissue following implantation into NOD SCID mice[23]. Selectively implanting sub-chondral bone 
increases spontaneous metastasis of MDA-MB-231 cells from the mammary fat pad to human bone 
implants by 40%[23]. Using the mammary intraductal (MIND) method to inject tumour cells directly into the 
fourth mammary ducts further increases metastasis rates to ~70%[23]. Using these optimised conditions, 
metastasis from the primary site to human bone could also be detected in 40%-50% mice injected with ER-
positive MCF7 or T47D breast cancer cells, 100% of mice injected with ER-positive BB3RC32 or BB2RC08 
PDXs and 20% of mice injected with ER-negative BB6RC37 PDXs [Table 1][23]. Interestingly, PDXs also 
metastasised to human bone implants following intra-cardiac injection (80% from BB3RC32, 80% from 
BB2RC08 and 30% from BB6RC27). Importantly, bone metastases have been shown to be more prevalent 
from ER-positive PDXs compared with ER-negative, with ER-negative preferentially metastasising to lung, 
which is in line with predicted metastasis patterns observed in breast cancer patients; no lung metastases 
have been observed from breast cancer cell lines[23]. When analysing data generated using these models, 
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several factors should be taken into account: simultaneous to injection of PDXs and ER-positive cell lines, 
mice were supplemented with oestradiol, and, although these cell types predominantly metastasised to 
human bone implants, metastasis to mouse bone was also detected. Oestradiol supplementation is not 
required for metastasis of ER-negative, MDA-MB-231 or SUM1315 cells, and these specifically spread to the 
human bone implants[23]. As oestradiol has been shown to stimulate ER-positive tumour metastasis to 
mouse bone[23,40], it is possible that this apparent tropism to mouse bone, seen in PDXs or ER-positive cell 
lines in this model, is influenced by this hormone, and this hypothesis is supported by work carried out by 
Yang et al.[54]. Using a similar model, in which non-tumour bearing human bone and human bone 
impregnated with MDA-MB-231-GFP breast cancer cells were implanted into opposite flanks of NOD SCID 
mice, tumour cells were found to spontaneously metastasise from the original bone metastases, specifically, 
to the contralateral non-tumour bearing human bone implant[54]. Similarly, the same research group showed 
that two out of five human primary tumour samples co-implanted with human bone were able to grow in 
this bone (HuP2, a metaplastic carcinoma, and HuP4, a ductal carcinoma); despite both of these tumours 
growing to 2-3 cm in diameter in the human bone grafts, metastasis to the contralateral non-tumour 
bearing human bone implants was only detected from HuP4. Interestingly, mice used in this study were not 
supplemented with oestradiol and metastasis to mouse bone was not observed. It must be noted, however, 
that metastases in the contralateral human bones were small (only detectable microscopically), and whether 
lack of metastasis to mouse bone is due to no tumours cells being disseminated in this site or metastases 
being too small to detect remains to be established. In this manuscript, the authors hypothesise that this 
apparent lack of metastasis to mouse bone is indicative of species specificity and that this model can be used 
to decipher between metastatic and non-metastatic breast cancer; however, as only one patient sample was 
metastatic, more data are required for these types of conclusion to be drawn[52]. These human bone models 
necessitate the use of immune-compromised mice; despite implanted bone demonstrating active 
haematopoiesis and production of human B cells, the lack of autoimmunity observed in these models 
suggests that human immune cells are not very active, and the presence of human T cells has not yet been 
investigated[23,51]. It is apparent that, although data from mouse models of human breast cancer metastasis to 
human bone implants are amassing, further research is required before we can explore the full potential of 
these models.
For experiments designed to determine the latter stages of bone metastasis in a human-specific 
environment, tumour cells can be seeded directly into subchondral bone discs of various sizes. These co-
cultures can subsequently be used for in vitro assays or can be implanted into NOD SCID mice for 
investigating parameters associated with tumour cell-bone cell interactions[53]. Importantly, molecular 
profiling performed in both the spontaneous metastasis and co-culture implant models has identified novel 
signaling pathways that have subsequently been confirmed to be clinically relevant in the bone metastatic 
process[6].
It should be noted that the use of human-specific models for research purposes are not a simple option. 
These models require appropriate ethical agreements to be in place as well as access to freshly resected 
femoral heads that need to be sectioned and implanted into mice/placed in culture within 2-3 h following 
surgical resection. Furthermore, to achieve consistent data, bone samples should be cut to a standard size; 
this accuracy necessitates the use of specialised equipment (as described in[23,53]). For researchers wishing to 
model the entire metastatic process from tumour growth in the mammary site to overt metastases in bone, 
this is lengthy and expensive. Tumour cells are injected four weeks following implantation of human bone, 
and, dependent on the tumour cells being tested, it can take a further 6-15 weeks before metastases are 
detected in this metastatic site [Table 1]. Injecting PDXs requires additional expansion of the tumour cells 
in NSG mice prior to implantation to ensure sufficient numbers of cells from the same patient are available 
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for experimental purposes, further adding time and expense to these experiments. Therefore, although 
human-to-human bone metastasis models provide useful, clinically relevant tools for investigating tumour 
cell-bone cell interactions and the metastatic process in a human-specific environment, their use is unlikely 
to supersede the cheaper, more commonly used intra-cardiac injection models of metastases to mouse bone.
Immune competent models
Transgenic models
Modelling breast cancer bone metastasis in immunocompetent models enables the researcher to assess how 
the immune system interacts with various stages of the metastatic process as well as interactions with anti-
cancer agents. Although there are multiple transgenic models in which genetic manipulation of genes 
including P53, TGFα, Myc, Wnt1, β-Catenin, NOTCH4, Cox2 ErbB-1 (neu) and SV40 results in 
spontaneously develop mammary cancers, from which metastasis to lung is commonplace, spontaneous 
metastasis to bone appears to be an extremely rare event and is almost never reported in the literature 
(reviewed in[55]). A possible exception to this is a transgenic mouse deficient in p53 and E-Cadherin in the 
mammary gland[56]. This Wcre;Cdk1F/F;Trp53F/F mouse shows pleomorphic similarities to the invasive lobular 
carcinoma seen in humans. Multifocal tumours spontaneously develop in ~74% of mice in several 
mammary glands, and, although the majority of mammary cells from these mice are ER-negative, 
occasional weak expression of ER was identified in low-grade tumours with ER status being inversely 
correlated to tumour stage. In this model, female mice whose primary tumours reached ~1 cm in diameter 
presented with extensive local invasion and metastasis to draining lymph nodes. Metastases were also 
detected in the skin, lungs, liver, gastrointestinal tract, pancreas and spleen. Interestingly, the authors also 
reported bone metastasis from several Wcre;Cdk1F/F;Trp53F/F mice; however, no indications of metastatic 
frequency or duration to detection of tumour cells in this site were reported, making it difficult to establish 
the usefulness of this model for studying bone metastasis per se[56].
Syngeneic models
Because bone metastases are rare from transgenic models, researchers have developed syngeneic models in 
which mouse mammary cancer cells are injected into recipient mice of a complementary background to 
those in which the cells were originally generated. These syngeneic models, however, do not permit use of 
human breast cancer cells or PDX. As the aetiologies of human and mouse mammary cancer metastases 
differ fundamentally, in that human breast cancer primarily metastasises to bone, whereas mouse mammary 
cancer preferentially metastasises to lung and almost never to bone, data from these models should be 
interpreted accordingly. These low rates of spontaneous bone metastasis may, in part, be due to biological 
differences between humans and mice: mouse cells have enhanced metabolic activity and longer telomerases 
compared to human cells, influencing oncogenesis and phenotypic differences[57]. Mammary tumours also 
develop from different cell lineages with mouse tumours originating from mesenchymal tissue and human 
tumours arising primarily from epithelial cells[57]. In addition, mouse mammary tumours are hormone 
independent, whereas the majority of human tumours that metastasise to bone are hormone responsive 
requiring higher concentrations of oestrogen to support their growth[58].
To address the issue of low rates of bone metastasis, researchers have produced bone trophic sublines of 
mouse mammary cancer cells via repeated in vivo passaging through bone. Orthotopic injection of some of 
these cell lines results in spontaneous metastasis to the mouse skeleton to varying degrees (20% from 4T1 
cells, 40%-60% from 4T1-2, 50% from KEP and 60%-80% from E0771)[6,33,59,60]. Primary tumours grow rapidly 
in these models and often need to be surgically removed to allow time for metastatic outgrowth to be 
detected in bone. Because all of these syngeneic cell lines also spontaneously metastases to lung and the lung 
metastases develop more rapidly than the bone metastases, bone metastatic deposits are often very small 
and difficult to detect on histological sections, complicating downstream analysis.
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Increased bone metastases rates and sizes can be achieved by introducing these cell lines via intra-cardiac 
injection. Osteolytic bone metastases can be detected in 70%-90% of mice following injection of 4T1-2, 
E0771 or Py8119 cells into the left cardiac ventricle, however lung and other soft tissue metastases are still 
prevalent in all of these model systems[60-62]. It therefore appears that the only way to model bone metastases 
in syngeneic model systems, without the complications associated with soft tissue metastases, is to inject 
tumour cells directly into the long bones (tibia/femur). Injecting mouse mammary cancer cells into their 
complementary mouse model results in high engraftment rates (up to 100%) and provides a useful tool for 
modelling tumour cell-bone cell interactions in an immune competent environment[60,61,63].
ASSESSMENT OF TUMOUR PROGRESSION IN BONE
Imaging in live animals
To enable analysis of tumour progression at the primary site and/or in bone in live animals, cell lines/PDXs 
are commonly pre-labelled with luciferase or fluorescent proteins before injection. Fluorescently-labelled 
tumours [Figures 2 and 3A][36] can be detected by placing the mouse under a light source and visualising 
through the correct filters using a simple machine such as a LightTools box. This method is cheap, quick 
and easy to use; however, the data are not quantifiable, and skeletal tumours can be difficult to observe until 
they are very large due to autofluorescence from the bone and light scatter. Bioluminescent imaging is much 
more sensitive, and tumours in bone can be detected using this method before they are visible on 
histological sections. This method therefore allows longitudinal, real time imaging studies of metastases 
development in bone. Importantly, data obtained from bioluminescence readouts[6,42,43] from tumours using 
a luminomior such an IVIS system are quantifiable, making this the preferred analytical method.
In addition to tumour growth, researchers are often interested in the effects that tumours and/or treatments 
are having on the bone microenvironment. Osteolytic lesion area and abnormal bone remodelling can be 
visualised and assessed weekly in vivo using a cabinet X-ray machine or by live µCT imaging of the affected 
bone(s) [Figure 3B][18,42,43,64]. Using in vivo µCT scanning, percentage changes in trabecular bone parameters 
and the size or number of osteolytic lesions can be measured over time as bone disease 
develops [Figure 4A-C]. In addition, following bone modulating therapy, effects on bone repair (new bone 
formation and bone density) can be mapped by overlaying bone images from the same mouse at different 
time points, as previously described[65,66].
Post-mortem analysis of bone metastases
With the exception of metastases from PDXs, bone lesions develop rapidly in mice, and animals should be 
monitored daily for changes in activity levels, mobility and onset of cachexia. For humane endpoint, mice 
should be euthanised before 20% body weight is lost, tumour progression impairs mobility or an animal 
appears to be in respiratory distress, taking into consideration local guidelines/approvals. To ensure that 
data obtained from experiments are comparable between groups, mice should be culled on the same day so 
that the experimental timeframe is standardised, the exception being for experiments designed to assess 
survival.
On termination of the experiment, mice should be examined closely for evidence of metastatic foci outside 
of bone. For studies in which tumour cells have been introduced via intra-cardiac injection, researchers 
should check accuracy of their technique before determining which mice should be selected for downstream 
analysis. For all tumour cell types, growth in the mediastinum surrounding the heart indicates that cells 
were not accurately injected into the left cardiac ventricle, and, specifically for MDA-MB-231 cells, tumour 
growth in the lungs suggests mis-injection into the right cardiac ventricle, from which bone metastases will 
not develop. Mice in which these mis-injections are detected should be excluded from the study. On 
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Figure 3. Common analysis of mouse models of bone metastases. In total, 1 × 105 4T1 or 5 × 105 MDA-MB-231 cells were injected into 
BALB/c or BALB/c nude mice, respectively. BALB/c mice were imaged two weeks after tumour cell injection and BALB/c nude mice 
imaged four weeks after tumour cell injection. Mice were culled for downstream analysis 24 h after imaging. (A) Bioluminescence 
imaging of tumours in the skeleton of BALB/c and BALB/c nude mice by IVIS (I) and florescence imaging of MDA-MB-231 tumours in 
the tibia of a BALB/c nude mouse by LightToolsTM. (B) Two-cross sections of longitudinal and cross-sectional micro-CT images (I) and 
whole leg X-ray images of tumour bearing bones from BALB/c nu/nu mice. (C) Two-dimensional 3 µM histological sections of tumour 
bearing tibiae from BALB/c mice following staining with Goldner’s trichrome (I) and H&E (II); tumour in bone is highlighted with a red 
outline. Data shown are previously unpublished images from the Ottewell laboratory.
dissection, all skeletal muscle from the forelimbs, hind limbs and vertebral column should be removed prior 
to downstream processing. Bone can then be flash frozen in liquid N2 for RNA/protein extraction or 
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Figure 4. In vivo µCT scanning to monitor cancer-induced bone disease development over time: (A) in vivo micro-CT scanner set up and 
area measured of a mouse right tibia; (B) in vivo micro-CT image analyses of a scanned right tibia using Drishti and ImageJ; and (C) 
representative in vivo micro-CT images of right tibiae from the same mouse over time (6-10 weeks post tumour cell injection) showing 
the development of osteolytic lesions. Data shown are previously unpublished images from the Lawson laboratory.
downstream analysis of dormant, DiD-labelled tumour cells in bone prior to storing at -80 °C 
[Figure 1A][38,42,43]. Alternatively, skeletal samples can be fixed for histology in 4% paraformaldehyde for 24-
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48 h. At this point, ex vivo µCT can be used to measure effects on trabecular and cortical bone [Figure 3B] 
before being decalcified in a solution of 1% PFA/0.5% EDTA for two weeks (changing the solution daily).
For histological analysis, decalcified paraffin-embedded bone is usually cut longitudinally into 3-5 µm 
sections and stained with haematoxylin-eosin (H&E) or Goldner’s trichrome [Figure 3C], and tumour 
burden is measured using an image analysis software package. H&E sections are also useful for measuring 
the number of cuboidal-shaped osteoblasts lining the bone. Osteoclast number and surface area of 
osteoclasts in contact with bone can be scored following visualisation with tartrate resistant acid 
phosphatase stain. It is also possible to carry out immunohistochemistry/immunofluorescence for a number 
of other molecular targets in histological sections of paraffin embedded and frozen sections of bone 
metastases, enabling researchers to investigate expression profiles of proteins that are of particular 
interest[19,30,53,67]. Additionally, serum can be assayed for the presence of bone turnover markers (such as 
TRAP5c for osteoclast activity and P1NP for osteoblast activity), hormones (oestrogen, inhibin, etc.), 
inflammatory factors or growth factors of interest. Methodologies for all of these routine procedures are 
described in detail in the following references[6,16,18,19,36,42,43].
DISCUSSION
The development of bone metastasis from breast cancer requires tumour cells to spontaneously develop at 
the primary site; secrete factors that prime bone for the arrival of tumour cells in this site[3,4,6,64]; undergo 
epithelial to mesenchymal transition[6]; disseminate into the circulation; extravasate in bone; home to the 
bone metastatic niche[7,8]; undergo a period of dormancy[10]; interact with the bone microenvironment to 
reduce anti-tumour immune regulation and expand the niches[7,8,68]; and grow in the bone forming osteolytic 
or mixed lesions[11-13]. Whilst we have excellent immune compromised models for investigating how human 
tumour cells colonise bone and interact with the bone microenvironment during the formation of 
metastases, including homing to the metastatic niche, metastatic dormancy and tumour outgrowth, these 
models primarily rely on human ER-negative, MDA-MB-231 cells, which exclusively form osteolytic lesions 
in bone[19,30,42,43]. The majority of human breast cancers that metastasise to bone are ER-positive, and, 
although human ER+ve MCF7 and T47D cells do metastasise to bone forming mixed lesions, to stimulate 
growth in a non-human environment, mice receive oestradiol supplementation, altering the bone 
microenvironment and making data difficult to interpret[40]. There is speculation amongst the research 
community that MCF7 and T47D cells will grow in mouse bone in the absence of oestradiol over extended 
time periods, possibly > 6 months. Further research is required to test this hypothesis as an ER-positive 
model of human breast cancer with long-term dormancy in bone would be highly reflective of human 
disease and may prove useful in increasing our understanding of dormancy/metastatic outgrowth. There are 
currently no immune competent models that allow us to investigate effects of immune regulation of 
metastasis from human breast cancer. With the advent of immunotherapies and increased appreciation of 
the importance of immune regulation in the metastatic process, researchers have put extensive efforts into 
producing an increasing library of syngeneic mouse models including bone homing variants of mouse 4T1, 
E0771 and Py8119 cells[6,60-62,68]. These models can be used to investigate lytic disease (4T1 and E0771) and 
mixed lesions (Py8119; unpublished observations from the Ottewell laboratory) and are generating exciting 
new data demonstrating the fundamental roles of the immune system in the regulation of bone metastasis 
that cannot be generated in immune-compromised mice[61,68]. However, as discussed above, it must be noted 
that there are fundamental differences between human and mouse breast cancers, as well as the human and 
mouse bone microenvironments[57,58]. Furthermore, mice do not express the same complement of immune 
cells subsets as humans[2], therefore data from these model systems cannot be interpreted independently and 
confirmatory experiments need to be performed in human samples. Currently, the most clinically relevant 
models appear to be those in which human PDXs spontaneously metastasise from the mammary gland to 
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human bone implants; these models allow the investigation of the growth of heterogeneous patient samples 
from different tumour subtypes and their ability to metastasise and interact with a human bone 
environment in a mouse with a semi-competent human immune system[23,52,54]. These models, however, are 
far from perfect and are expensive and difficult to run. It is unclear how active the human B cells are in this 
model and whether any other human immune cell subsets are present; further work is required to establish 
this. A mouse model of human breast cancer to human bone metastasis with a fully competent immune 
system would be a highly relevant tool. Extensive work has been carried out by various research groups to 
make mouse models with a human-specific immune system for research purposes. In these models, NSG 
mice are irradiated prior to injection of human haematopoietic stem cells; the resulting mice have been 
successfully used to show effects of immunotherapies in various cancer types including breast cancer[69-71]. It 
would be interesting to see if the same process could be used to produce a mouse model of human breast 
cancer metastasis to human bone with a competent human immune system and whether this would be 
possible given the difficulties of obtaining all three samples (bone, primary tumour and haematopoietic 
stem cells) from the same donor to avoid auto immunity.
In conclusion, there is a large array of mouse model systems available to researchers for investigating 
various parameters associated with breast cancer bone metastasis. When used in combination, these model 
systems cover most aspects associated with the metastatic process including growth at the primary site, 
spontaneous spread to bone, homing to the metastatic niche, dormancy and metastatic outgrowth. Models 
are also available to investigate the effects of immune cells on these processes. However, to date, there is not 
one model system that covers all of the processes, and there are no systems which reliably model 
spontaneous development of the primary tumour followed by bone metastasis. Researchers must therefore 
select the most appropriate model system(s) for their research question and interpret their data accordingly, 
giving special consideration to the need for experiments to be performed either with multiple cell lines or in 
multiple systems before reliable conclusions can be made.
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